Fate Therapeutics (FATE) Misses Q1 EPS by 4c
Get Alerts FATE Hot Sheet
Join SI Premium – FREE
Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Etsy upgraded to buy at BofA on durable growth, buyback potential
- Twin Disc (TWIN) Tops Q4 EPS by 16c
- Advance Auto Parts falls on revenue miss, weak guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share